You have to look at this from the manufacturer's / company's POV. Aggressive marketing isn't new in the Pharma business -- especially for blockbuster drugs (Viagra is an example). A blockbuster drug is one for which the sales exceed $1 billion in the financial year [
1]. Aggressive Sales comes from aggressive Marketing. I have worked with Pharma companies as a business consultant and their marketing ploys are crafty, to say the least. They have wealth (bottomless pits of cash), a battery of lawyers (a tank of sharks), strong lobbies (long arms shoved into all the right pockets), and they know how to twist data (most marketers are outright liars). I have routinely seen pharma talent crossover into litigious industries such as tobacco -- both industries need strong-arm tactics to thrive. Aggression is the norm in the pharma sector. Aggressive politics and aggressive business tactics can both be dirty -- and when the two come together, it's called the pharmaceutical industry.
As for AndroGel:
1. There is HEAVY demand for Testosterone -- from all quarters and populations. TRT is growing dramatically. Apparently, sales of Testosterone products have surpassed the sales for Viagra. This is a big deal -- Pfizer literally wrote the textbook on blockbuster drugs (with Viagra showing the way).
2. Gel based products are far more convenient than IMs (no self-injecting, no doc visits). Plus they can be discreet as well. (No disposing of needles, etc.)
3. It's a loop -- more sales means more advertising, and more advertising often means more sales. AndroGel is a blockbuster drug -- US sales were in the range of $1.4 billion in 2013 [
2]. It is among the top 40 products sold in the US market [
3] (which is the largest drug market in the world). Believe me -- this is BIG. There is a LOT at stake for the company and its shareholders. IMs cannot compete -- I believe the
worldwide sales for Nebido (T Undecanoate) in 2013 was in the range of $140 million (calculated using 2010 data and an optimistic growth rate of 30%) [
4].
Compare the worldwide sales of Nebido ($140 million) with US sales of AndroGel ($1.4 billion) -- that's 10 times the sales volume. Where would you put your money? (I chose Nebido as an example because it is designed for convenience (1 injection every 12 weeks), and is well-advertised.)
Most people don't have the time, or the enthusiasm, to study gels vs. IMs -- or even research the side-effects, etc. Most people also watch a lot of TV and believe everything big companies say -- which is why we need forums like this one.